GCP
EDIT icon

GSA Capital Partners’s Editas Medicine EDIT Stock Holding History

GSA Capital Partners’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.19M Sell
367,147
-67,266
-15% -$197K 0.08% 399
2026
Q1 		$1.07M Sell
434,413
-134,396
-24% -$284K 0.07% 457
2025
Q4 		$1.17M Buy
+568,809
New +$1.64M 0.1% 278
2025
Q3 		– Sell
-82,343
Closed -$181K – 1762
2025
Q2 		$181K Buy
+82,343
New +$135K 0.01% 1533
2024
Q4 		– Sell
-182,725
Closed -$623K – 1705
2024
Q3 		$623K Buy
182,725
+86,020
+89% +$374K 0.05% 774
2024
Q2 		$452K Buy
96,705
+49,303
+104% +$278K 0.03% 1030
2024
Q1 		$352K Buy
+47,402
New +$394K 0.03% 1112
2023
Q4 		– Sell
-20,141
Closed -$157K – 1591
2023
Q3 		$157K Buy
+20,141
New +$173K 0.01% 1329
2023
Q2 		– Sell
-20,549
Closed -$149K – 1607
2023
Q1 		$149K Buy
20,549
+1,803
+10% +$16K 0.01% 1306
2022
Q4 		$166K Sell
18,746
-1,760
-9% -$19.3K 0.02% 1229
2022
Q3 		$251K Sell
20,506
-48,494
-70% -$756K 0.03% 1049
2022
Q2 		$816K Buy
69,000
+56,876
+469% +$762K 0.12% 221
2022
Q1 		$231K Buy
12,124
+923
+8% +$17.2K 0.03% 1081
2021
Q4 		$297K Buy
11,201
+4,337
+63% +$149K 0.04% 938
2021
Q3 		$282K Buy
+6,864
New +$376K 0.03% 1061
2019
Q3 		– Sell
-15,817
Closed -$391K – 1471
2019
Q2 		$391K Sell
15,817
-16,283
-51% -$389K 0.04% 821
2019
Q1 		$785K Buy
+32,100
New +$727K 0.08% 426
2018
Q2 		– Sell
-26,285
Closed -$871K – 1741
2018
Q1 		$871K Buy
+26,285
New +$937K 0.05% 751
2017
Q4 		– Sell
-27,800
Closed -$667K – 1611
2017
Q3 		$667K Buy
+27,800
New +$529K 0.05% 774

Other funds holding EDIT

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

GSA Capital Partners's EDIT Position: Q2 2026 in Review

GSA Capital Partners reduced its Editas Medicine (EDIT) stake by 15% in Q2 2026, selling an estimated $197K and leaving 367,147 shares worth $1.19M. The position accounts for 0.08% of the portfolio, ranked #399.

GSA Capital Partners first reported a position in EDIT in Q3 2017 and has held it in 19 quarters since. 215 funds tracked by Wall St. Rank hold EDIT as of Q2 2026.

  • GSA Capital Partners held 367,147 shares of Editas Medicine worth $1.19M as of Q2 2026.
  • GSA Capital Partners sold 67,266 Editas Medicine shares in Q2 2026, an estimated $197K.
  • Editas Medicine made up 0.08% of GSA Capital Partners's portfolio in Q2 2026, its #399 holding.
  • GSA Capital Partners first reported a position in Editas Medicine in Q3 2017 and has held it in 19 quarters since.
  • 215 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.